SCHEMBL3064987

SCHEMBL3064987

Cc1cnccc1C(=O)N(Cc1ccccc1Cl)c1cccc(C)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.45
NOS3 P29474 2/20 0.44
NOS1 P29475 2/20 0.44
NOS2 P35228 2/20 0.44
ALDH1A1 P00352 7/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
GLA P06280 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.39
RECQL P46063 1/20 0.39
NR3C1 P04150 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SGMS2 Q8NHU3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054615 0.91 NOS3 (0.45) KDM4CNOS3NOS1NOS2ALDH1A1
SCHEMBL3064588 0.87 NOS3 (0.44) KDM4CNOS3NOS1NOS2ALDH1A1
SCHEMBL3065345 0.85 NOS3 (0.51) NOS3NOS1NOS2ALDH1A1MAPT
SCHEMBL3057326 0.85 TRPM8 (0.51) KDM4CALDH1A1MAPTGLANPSR1
SCHEMBL3053511 0.85 TSPO (0.51) KDM4CALDH1A1MAPTLMNAMEN1
SCHEMBL3058487 0.84 GPBAR1 (0.46) KDM4CNOS3NOS1NOS2ALDH1A1
SCHEMBL3058741 0.81 NOS3 (0.48) NOS3NOS1NOS2ALDH1A1MAPT
SCHEMBL3061190 0.81 NOS2 (0.54) KDM4CNOS3NOS1NOS2GPBAR1
SCHEMBL3061956 0.81 NOS3 (0.50) NOS3NOS1NOS2POLBNAMPT
SCHEMBL3058702 0.81 TSPO (0.51) NOS3NOS1NOS2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 2010-10-14 US disclosed
CN-101405268-A Amide derivatives and their use for the treatment of protein-related diseases NOVARTIS AG (CH) 2009-04-08 CN disclosed
EP-2001851-A2 AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES Novartis AG (CH) 2008-12-17 EP disclosed
WO-2007110237-A2 AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES NOVARTIS AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS HRH4, CNR1, CNR2 KDM4C 649/4885NOS3 3019/4885NOS1 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.